Bristol-Myers Squibb is set to transform its drug development processes by implementing Anthropic's Claude AI model across its 30,000-strong workforce. This initiative aims to speed up the search for new medicines while improving the efficiency of both engineering and AI teams within the pharmaceutical giant.
The integration will focus on using Claude Code, a tool designed for developers, enabling Bristol-Myers Squibb to enhance progress in various operational areas, including research, drug development, manufacturing, and commercial and medical affairs. Greg Meyers, the company’s chief digital and technology officer, stated that the goal is to unify disparate data sources through a cohesive AI framework. "A lot of it is us avoiding having to build basic infrastructure tooling, so that we can really focus on the use cases that are going to bring more medicines to more patients faster," he explained.
One practical application already in place is Claude's role in generating regulatory reports from clinical trial data. This task requires the AI to understand both the regulatory strategies of Bristol-Myers Squibb and the specific style of its existing documentation. This use case shows how AI can save time while ensuring compliance and consistency in reporting.
For Anthropic, this partnership marks a strategic entry into the life sciences sector, which Eric Kauderer-Abrams, head of life sciences at Anthropic, has identified as a key investment area. Since launching Claude for Life Sciences in October 2022, the company has promoted its vision of employing AI throughout all life science operations. Kauderer-Abrams emphasized, "It's not just about using AI to design new drugs, or not just about using AI to make clinical trials go faster, but really using AI end-to-end through every part of the process of operating a life science organization."
This collaboration with Bristol-Myers Squibb fits into a broader trend, as Anthropic has actively expanded its enterprise initiatives across various sectors. Earlier this week, the firm announced an alliance with KPMG and introduced a series of AI agent templates for financial services, with major institutions like Goldman Sachs and Citi already participating. Anthropic's competitor, OpenAI, has similarly pursued partnerships in the life sciences, working with companies such as Moderna and Novo Nordisk.
Despite the significant investment in AI technologies within the pharmaceutical sector, many practitioners remain cautious. The Wall Street Journal highlighted that while billions have been poured into AI solutions, concrete and widespread results from these investments are still largely unverified. As Bristol-Myers Squibb embarks on this journey with Anthropic, the industry will closely watch the outcomes, hoping to confirm the potential of AI to revolutionize drug development and healthcare delivery.
